Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

HemaTrax: Lineage-resolved prediction of hematotoxicity for human-relevant drug development

Ziel

Hematotoxicity is a major determinant of treatment intensity and dosing in cancer therapy and a frequent cause of late-stage attrition in drug development. Current pre-clinical assessment strategies provide limited mechanistic insight into how drugs perturb human hematopoiesis. Animal models often translate poorly to human lineage sensitivities and rely on late aggregate outcomes, such as cytopenias, while human in-vitro assays typically lack bone-marrow niche context. As a result, lineage-specific toxicity mechanisms remain difficult to anticipate, particularly for complex or combination therapies.

This project will test a mechanism-informed framework (HemaTrax) for predicting hematotoxicity. HemaTrax integrates human hematopoietic niche co-culture systems with early lineage-resolved single-cell profiling and computational modelling of gene-regulatory perturbations. Drug-induced changes in transcription-factor activity detected at early differentiation stages will be mapped onto lineage-specific regulatory programmes derived from a large human bone-marrow reference atlas to predict downstream hematopoietic effects.
The main objective is to determine whether early transcription-factor perturbations predict clinically observed hematotoxicity patterns. Model-derived predictions will be systematically benchmarked against longitudinal hematological data from retrospective patient cohorts treated with selected chemotherapeutic agents.

If successful, this framework will establish a human-relevant and mechanistically interpretable basis for hematotoxicity assessment, enabling improved pre-clinical decision-making and informing the design of prospective clinical validation studies. More broadly, the approach supports regulatory efforts to increase human relevance while reducing reliance on animal experimentation.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

UNIVERSITAT BASEL
Netto-EU-Beitrag
€ 150 000,00
Adresse
PETERSPLATZ 1
4051 Basel
Schweiz
Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Begünstigte (1)